Melinta Therapeutics, Inc. (MLNT)


Melinta Therapeutics, Inc. (MLNT)

$2.49 USD

0.20 (-7.43%)

Updated Aug 20 4:00pm

Add MLNT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 329 in Biotech

See all “A” rated Strong Buy stocks

MLNT Daily Price Range
MLNT 52-Week Price Range

MLNT Stock Chart More Charts


MLNT Price/Volume Stats

Current price $2.49
Prev. close $2.69
Day low $2.35
Day high $2.68
50-day MA $4.16
200-day MA $5.56
52-week high $24.90
52-week low $1.62
Volume 327,156
Avg. volume 1,310,503
Dividend yield N/A
Market Cap 34.24M

Melinta Therapeutics, Inc. (MLNT) Company Bio


Melinta Therapeutics, Inc., formerly Cempra, Inc., is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP). Solithromycin has therapeutic potential and activity to target pathogenic bacteria. It has completed two pivotal Phase III trials for solithromycin to treat CABP, as of December 31, 2016. Its Fusidic acid is an antibiotic and the Company is exploring its use for the long-term oral treatment for refractory bone and joint infections (BJI), including prosthetic joint infections, which are caused by staphylococci, including S. aureus, methicillin-resistant S. aureus and other gram-positive bacteria.





MLNT News Stream


Event/Time News Detail
Loading, please wait...

MLNT Social Stream


Loading social stream, please wait...

View Full MLNT Social Stream

MLNT Returns

1-mo -35.66%
3-mo -15.88%
6-mo -60.16%
1-year -89.52%
3-year -99.56%
5-year -98.94%
YTD -36.96%
2018 -95.00%
2017 12.86%
2016 -91.01%
2015 32.41%
2014 89.75%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.4368 seconds.